Clinical Trial

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-04-13; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2024-07-25
Status change: Not Yet Recruiting → Recruiting 2022-08-02
Trial Details
NCT Number NCT05327530
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Conditions Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment 256 participants
Start Date 2022-08-17
Primary Completion 2025-06-20 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-24